ArthritoMab™ Antibody Cocktail
Please register to view price.
Bulk pricing available. Please Inquire.
ArthritoMab™ Antibody Cocktail is a cocktail of 4 monoclonal antibodies to collagen II (CII) used for inducing arthritis in the anti-Collagen Antibody Induced Arthritis (CAIA) model.
Overview
Inducing severe arthritis in mice typically within 24-48 hrs using a cocktail of monoclonal antibodies selected for their epitope specificity.
Collagen-induced arthritis (CIA) in mice is widely used as an experimental model for rheumatoid arthritis (RA) in humans. CIA is mediated by autoantibodies, which bind to a particular region of type II collagen (CII). The ability to induce arthritis using this arthritogenic antibody cocktail provides an efficient protocol for the induction of antibody-mediated arthritis that can be used as a shorter, more synchronized alternative to the CIA model.
Benefits of the CAIA model
- Length of study: Arthritis develops in mice typically within 24-48 hr allowing the completion of a study within 2 weeks reducing the number of assessments and scoring periods.
- Reduced group size: Rate of incidence is nearly 100% depending on the strain allowing for smaller group sizes.
- Synchronization: onset of disease is synchronized between animals simplifying treatment schedules.
- Susceptibility: Arthritis is induced not only in CIA-susceptible DBA/1 and B10.RIII mice, but also in some CIA-resistant mice, such as Balb/c.

Abreviations:
- Anti-Collagen Induced arthritis (ACIA)
- Monoclonal Antibody induced arthritis (mAb-RA)
- Collagen Antibody Induced Arthritis (CAIA)
Data/Specifications
Epitope specificity
This arthritogenic cocktail of 4 monoclonal antibodies bind to the well-defined epitopes C11b, J1, D3 and U1, which are spread over the entire CII (CB8, CB10 and CB11 fragments), possibly encouraging better immune complex formation on the cartilage surface for the initiation of arthritis.
Clones
Comprised of 4 antibodies to Collagen II:
- clone M2139 (IgG2b)
- clone CIIC2 (IgG2a)
- clone UL1 (IgG2b)
- clone CIIC1 (IgG2b)
Susceptibility
- Balb/c
- DBA/1
- B10.RIII
- C57Bl/6


Literature/Support
- ArthritoMab™ Antibody Cocktail Product Insert
- Whitepaper: For induction of arthritis in the Collagen Antibody Induced Arthritis (CAIA)model: a shorter, more synchronized alternative to the classic CIA model.
- On-demand Webcast: Collagen Antibody-Induced Arthritis:A Short, Synchronised and Rapid Rheumatoid Arthritis Model that can Reduce Time and Expenditure by 85%
- Poster: ArthritoMab™ Antibody Cocktail: a cocktail of anti-collagen type II antibodies induce a synchronized model of Arthritis in just 12 days.
- Publication: Efficient promotion of collagen antibody induced arthritis (CAIA) using four monoclonal antibodies specific for the major epitopes recognized in both collagen induced arthritis and rheumatoid arthritis. Nandukamar & Holmdahl Journal of Immunological Methods 304 (2005) 126 – 136
References/Citations: | How the ArthritoMab™ Antibody Cocktial was used: |
| Pharmacological targeting reveals distinct roles for CXCR2/CXCR1 and CCR2 in a mouse model of arthritis. Min S. et al. Biochemical and biophysical research communications. 2010; 391(1):1080-6. | Induce arthritis in 8- and 10-week old BALB/c mice. On day 0, mice were injected intraperitoneally with 4 mg of ArthritoMab. On day 3, mice were boosted intraperitoneally with 50 ug of lipopolysacharide in 200 ul sterile PBS. |
| Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis. McCann FE, et al. Arthritis Res Ther. 2010 Jun; 12(3):R107. | Induced arthritis experiments using six-week-old male BALB/c mice. |
| Pharmacological targeting reveals distinct roles for CXCR2/CXCR1 and CCR2 in a mouse model of arthritis. Soo-Hong Min et al., Biochemical and Biophysical Research Communications 391 (2010) 1080-1086. | Induce arthritis in Female BALB/c mice between 8 and 10 weeks of age. Each mouse received a 4mg intraperitoneal injection on day 0 and a 50ug boost of LPS on day 3. |
| The novel small molecule drug Rabeximod is effective in reducing disease severity of mouse models of autoimmune disorders M Hultqvist, K S Nandakumar, U Björklund, and R Holmdahl Ann Rheum Dis, Jan 2009; 68: 130 - 135. | Induce arthritis in BALB/c mice. On day 0, 100 mg/kg (2 mg/mouse) of ArithritoMab was injected to induce arthritis. At day 5 or 3 respectively, lipopolysacharide (LPS) was injected intraperitoneally (50 ug/mouse) to enhance the incidence. |
| Mast cell chymase contributes to the antibody response and the severity of autoimmune arthritis. Sofia E. Magnusson, Gunnar Pejler, Sandra Kleinau, and Magnus Åbrink FASEB J, Mar 2009; 23: 875 - 882. | Induce arthritis in genetically modified mice backcrossed to the arthritis-susceptible DBA/1 strain. Each mouse recieved a total of 4mg of ArthritoMab transferred intravenously in two consecutive days. On the fourth day, a 50ug boost of LPS was given by intraperitoneal injection. |
| Dominant-Negative Inhibitors of Soluble TNF Attenuate Experimental Arthritis without Suppressing Innate Immunity to Infection Jonathan Zalevsky et al., J. Immunol., Aug 2007; 179: 1872 - 1883. | Induce arthritis in Male BALB/c mice. Each mouse recieved 25 mg/kg of ArthitoMab through i.v. injection on day 0 and a 2.5 mg/kg boost of LPS given by i.p. 72 h later. |
| PRECLINICAL EFFICACY OF XPROTM 1595, A BIOLOGIC DOMINANT-NEGATIVE INHIBITOR OF SOLUBLE TNF THAT BLOCKS INFLAMMATION WITHOUT SUPPRESSING INNATE IMMUNITY J. Zalevsky, P. Wong, C. O'Brien, and D.E. Szymkowski Ann Rheum Dis, Jun 2006; 65: 142. |
How To Use
Applications
- In vivo: induce disease in the collagen antibody induced arthritis model
- bind collagen in vivo
- impair cartilage formation by chondrocytes in vitro
- inhibit assembly of CII in vitro
- inhibit collagen fibrillogenesis in vitro
- Administer antibody cocktail on day 0*
- Boost with LPS on day 3
- Terminate on day 12